A recent pan-cancer analysis of gene signature demonstrated that tumors with comparatively higher Hh activity, especially in uterine corpus endometrial carcinoma, skin cutaneous melanoma and ovarian serous cystadenocarcinoma, display upregulated PD-L1 and relatively fewer immune effectors (129), indicating possible links between Hh signaling and PD-L1-mediated tumor immune responses. The gene discussed is CD274; the disease is cancer.